The stock price of Evaxion Biotech A/S ADR (NASDAQ: EVAX) has plunged by -12.30 when compared to previous closing price of 3.09, but the company has seen a -36.24% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-14 that COPENHAGEN, Denmark, January 14, 2025 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company’s previously disclosed ratio change of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective.
Is It Worth Investing in Evaxion Biotech A/S ADR (NASDAQ: EVAX) Right Now?
The stock has a 36-month beta value of -0.24. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
On January 22, 2025, the average trading volume of EVAX was 83.02K shares.
EVAX’s Market Performance
EVAX stock saw a decrease of -36.24% in the past week, with a monthly decline of -43.32% and a quarterly a decrease of -80.00%. The volatility ratio for the week is 21.33%, and the volatility levels for the last 30 days are 13.97% for Evaxion Biotech A/S ADR (EVAX). The simple moving average for the last 20 days is -35.88% for EVAX stock, with a simple moving average of -80.21% for the last 200 days.
Analysts’ Opinion of EVAX
Many brokerage firms have already submitted their reports for EVAX stocks, with Ladenburg Thalmann repeating the rating for EVAX by listing it as a “Buy.” The predicted price for EVAX in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on April 02, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see EVAX reach a price target of $14. The rating they have provided for EVAX stocks is “Buy” according to the report published on February 12th, 2024.
EVAX Trading at -57.88% from the 50-Day Moving Average
After a stumble in the market that brought EVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.02% of loss for the given period.
Volatility was left at 13.97%, however, over the last 30 days, the volatility rate increased by 21.33%, as shares sank -38.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -79.23% lower at present.
During the last 5 trading sessions, EVAX fell by -36.24%, which changed the moving average for the period of 200-days by -84.94% in comparison to the 20-day moving average, which settled at $4.23. In addition, Evaxion Biotech A/S ADR saw -35.89% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for EVAX
Current profitability levels for the company are sitting at:
- -4.57 for the present operating margin
- 1.0 for the gross margin
The net margin for Evaxion Biotech A/S ADR stands at -3.48. The total capital return value is set at -0.99. Equity return is now at value -803.07, with -84.81 for asset returns.
Currently, EBITDA for the company is -21.4 million with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of 8.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.80.
Conclusion
To sum up, Evaxion Biotech A/S ADR (EVAX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
